Skip to main content

Research News

Crack GPAT — Prepare for GPAT Online 
  • Study Uncovers Genetic Risk Factors for Heart Failure

    In a new study co-led by investigators at the United States Department of Veterans Affairs and Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, a global team of scientists conducted one of the largest genetic association studies on heart failure to date. Using genomic data from over 90,000 heart failure patients and more than a million controls, the team identified 39 genetic mutations associated with heart failure, 18 of which had not been reported previously.

  • New antibiotic from microbial dark matter could be powerful weapon against superbugs

    Antimicrobial resistance is a major problem for human health and researchers worldwide are looking for new solutions. “We urgently need new antibiotics to combat bacteria that become increasingly resistant to most clinically used antibiotics,” says Dr. Markus Weingarth, a researcher from the Chemistry Department of Utrecht University.

  • Researchers fully Sequence the Y Chromosome for the First Time

    Led by the National Human Genome Research Institute (NHGRI), a team of researchers at the National Institute of Standards and Technology (NIST) and many other organizations used advanced sequencing technologies to read out the full DNA sequence of the Y chromosome a  region of the genome that typically drives male reproductive development.

  • FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

    The Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

  • Merck breast cancer medicine meets trial endpoint

    Merck known as MSD outside of the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

  • Gene Mutation May Explain why Some Don’t Get Sick from COVID-19

    People who contract COVID-19 but never develop symptoms the so-called super dodgers may have a genetic ace up their sleeve. They’re more than twice as likely as those who become symptomatic to carry a specific gene variation that helps them obliterate the virus, according to a new study led by UC San Francisco researchers. 

  • Machine Learning : Artificial Neural Networks Localize Extrasystoles

    Additional heartbeats from cardiac chambers, so-called ventricular extrasystoles, may be associated with severe diseases. Researchers at Karlsruhe Institute of Technology (KIT) use machine learning for their non-invasive localization. This may facilitate and improve future diagnosis and therapy. The researchers use artificial neural networks trained with synthetic data from a realistic simulation model. They report in Artificial Intelligence in Medicine.

  • A Common Diabetes Drug Has a Surprising Side Gig : Muscle Protector

    University of Utah Health researchers have discovered that Metformin, a common drug that’s been used in diabetes treatment for more than half a century, has surprising applications on a cellular level. It can target “zombie-like cells,” called senescent cells, which impact muscle function. Senescent cells secrete factors associated with inflammation that may underlie fibrotic tissue, a hardening or scarring of tissues. Metformin also reduces muscle atrophy. Their findings published in Aging Cell.

  • Unraveling a protein that may inspire a new biotechnology tool

    Scientists have unraveled the step-by-step activation process of a protein with a deep evolutionary history in all domains of life, opening the door to harnessing its functions for use as a biotechnology tool.

    The protein belongs to the “superfamily” of Argonaute proteins, which previous research has suggested to be involved in gene silencing, a fundamental process known as RNA interference.

  • Asprius Lifesciences developed treatment for Diabetic Neuropathy

    Asprius Lifesciences has announced that it has developed treatment for Diabetic Neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination that holds promise in treating peripheral neuropathy.

Subscribe to Research News